Interferon-α therapy in polycythemia vera and essential thrombocythemia

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 5, 1997, Pages 463-472

  Elliott, Michelle A ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Essential thrombocythemia; Pathogenesis; Polycythemia vera; Side effects; Treatment

Indexed keywords

ALPHA INTERFERON;

ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MECHANISM; ERYTHROCYTOSIS; FATIGUE; HEADACHE; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; NAUSEA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REMISSION; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS;

EID: 0030815259     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996123     Document Type: Article

References (96)

1. Dameshek W: Some speculations on the myeloproliferative syndromes (editorial). Blood 6:372-375, 1951.
2. Gilbert HS: The spectrum of myeloproliferative disorders. Med Clin North Am 57:355-393, 1973.
3. Michiels JJ: The myeloproliferative disorders: An historical appraisal and personal experiences. Leukemia Lymphoma 22 (suppl 1):1-14, 1996.
4. Dickstein JI, JW Vardiman: Hematopathologic findings in the myeloproliferative disorders. Semin Oncol 22:355-373, 1995.
5. Michiels JJ, ME Prins, A Hagermeijer, et al: Philadelphia chromosome-positive thrombocythemia and megakaryoblast leukemia. Am J Clin Pathol 88:645-652, 1987.
6. Michiels JJ, FJ ten Kate: Erythromelalgia in thrombocythemia of various myeloproliferative disorders. Am J Hematol 39:131-136, 1992.
7. Georgii A, T Buhr, G Buesche, et al: Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leukemia Lymphoma 22(suppl 1):15-29, 1996.
8. Bilgrami S, BR Greenberg: Polycythemia rubra vera. Semin Oncol 22:307-326, 1995.
9. Tefferi A, MN Silverstein, HC Hoagland: Primary thrombocythemia. Semin Oncol 22:334-340, 1995.
10. Bellucci S, M Janvier, G Tobelem, et al: Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 58: 2440-2447, 1986.
11. Colombi M, F Radaelli, L Zocchi, et al: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 67:2926-2930, 1991.
12. Fenaux P, M Simon, MT Caulier, et al: Clinical course of essential thrombocythemia in 147 cases. Cancer 66:549-556, 1990.
13. Cortelazzo S, P Viero, G Finazzi, et al: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990.
14. Cortelazzo S, G Finazzi, M Ruggeri, et al: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.
15. Gruppo Italiano Studio Policitemia: Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656-664, 1995.
16. Thomas DJ, J Marshall, RW Russell, et al: Effect of haematocrit on cerebral blood-flow in man. Lancet 2:941-943, 1977.
17. Pearson TC, G Wetherley-Mein: Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219-1222, 1978.
18. Berk PD, JD Goldberg, PB Donovan, et al: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132-143, 1986.
19. Barbui T, S Cortelazzo, P Viero, et al: Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function. Eur J Cancer Clin Oncol 19:1593-1599, 1983.
20. Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1-12, 1984.
21. van Genderen PJ, JJ Michiels: Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 23:73-77, 1994.
22. Tartaglia AP, JD Goldberg, PD Berk, et al: Adverse effects of anti-aggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172-176, 1986.
23. Michiels JJ, J Abels, J Steketee, et al: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471, 1985.
24. Scheffer MG, JJ Michiels, ML Simoons, et al: Thrombocythemia and coronary artery disease. Am Heart J 122:573-576, 1991.
25. Michiels JJ, PJ Koudstaal, AH Mulder, et al: Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 43:1107-1110, 1993.
26. Shibata K, Y Shimamoto, K Suga, et al: Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation - A brief review of recent literature. Acta Haematol 91:84-88, 1994.
27. Lofvenberg E, I Nordenson, A Wahlin: Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet 49:57-67, 1990.
28. Weinfeld A, B Swolin, J Westin: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 52:134-139, 1994.
29. Isaacs A, J Lindenmann: Virus interference. I. The interferon. Proc R Soc 147:258, 1957.
30. Friedman RM: Antiviral activity of interferons. Bacteriol Rev 41:543-567, 1977.
31. Bloom BR: Interferons and the immune system. Nature 284:593-595, 1980.
32. vant Hull E, H Schellekens, B Lowenberg, et al: Influence of interferon preparations on the proliferative capacity of human and mouse hone marrow cells in vitro. Cancer Res 38:911-914, 1978.
33. Moritz T, H Kirchner: The effect of interferons on cellular differentiation. Blut 53:361-370, 1986.
34. Gutterman JU: Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 91:1198-1205, 1994.
35. Allan NC, SM Richards, PC Shepherd: UK Medical Research Council randomised, multicentre trial of interferon-alpha for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345: 1392-1397, 1995.
36. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994.
37. Muller EW, JT de Wolf, R Egger, et al: Long-term treatment with interferon-alpha 2h for severe pruritus in patients with polycythaemia vera. Br J Haematol 89:313-318, 1995.
38. Turri D, ME Mitra, R di Trapani, et al: Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 76:75-77, 1991.
39. Silver RT: Interferon-alpha 2b: A new treatment for polycythemia vera. Ann Intern Med 119:1091-1092, 1993.
40. Cimino R, V Rametta, C Matera, G Mele, et al: Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am J Hematol 44:155-157, 1993.
41. Finelli C, L Gugliotta, B Gamberi, et al: Relief of intractable pruritus in polycythemia vera with recombinant interferon-alpha. Am J Hematol 43:316-318, 1993.
42. Papineschi F, A Bucalossi, E Capochiani, et al: Recombinant alpha 2a interferon and polycythemia vera: Clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur J Haematol 53:213-217, 1994.
43. Sacchi S, P Leoni, M Liberati, et al: A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol 68:247-250, 1994.
44. Foa P, P Massaro, S Ribera, et al: Role of interferon alpha-2a in the treatment of polycythemia vera. Am J Hematol 48:55-57, 1995.
45. Taylor PC, G Dolan, JP Ng, et al: Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: A study of 17 patients and an analysis of published data. Br J Haematol 92:55-59, 1996.
46. Lazzarino M, A Vitale, E Morra, et al: Therapy of essential thrombocythemia with alpha-interferon: Results and prospects. Eur J Haematol 45(suppl 52):15-21, 1990.
47. Gisslinger H, A Chott, W Scheithauer, et al: Interferon in essential thrombocythaemia. Br J Haematol 79(suppl 1):42-47, 1991.
48. Kasparu H, M Bernhart, O Krieger, et al: Remission may continue alter termination of recombinant rIFN α-2b treatment for essential thrombocythemia. Eur J Haematol 48:33-36, 1992.
49. Giles FJ: Maintenance therapy in the myeloproliferative disorders: The current options. Br J Haematol 79(suppl 1):92-95, 1991.
50. Sacchi S, A Tabilio, P Leoni, et al: Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann Hematol 63: 206-209, 1991.
51. Sacchi S, A Tabilio, P Leoni, et al: Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment. Ann Hematol 66:245-246, 1993.
52. Middelhoff G, I Boll: A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann Hematol 64:207-209, 1992.
53. Rametta V, F Ferrara, V Marttoli, et al: Recombinant interferon alpha-2b as treatment of essential thromhocythaemia. Acta Haematol 91:126-129, 1994.
54. Pogliani EM, F Rossini, I Miccolis, et al: Alpha interferon as initial treatment of essential thrombocythemia. Analysis after two years of follow-up. Tumori 81:245-248, 1995.
55. Ganser A, C Carlo-Stella, J Greher, et al: Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 70:1173-1179, 1987.
56. Broxmeyer HE, L Lu, E Platzer, et al: Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 131: 1300-1305, 1983.
57. Carlo-Stella C, M Cazzola, A Gasner, et al: Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with rnyeloid metaplasia. Blood 70:1014-1019, 1987.
58. Means RT Jr, SB Krantz: Inhibition of human erythroid colony-forming units by interferons: Different modes of action for α, β, and γ IFNs (abstract). Blood 78(suppl):306A, 1991.
59. Gugliotta L, GP Bagnara, L Catani, et al: In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 71:177-181, 1989.
60. Castello G, R Lerza, A Cerruti, et al: The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 87:621-623, 1994.
61. Wang JC, P Liao, A Wong: Recombinant α-interferon inhibits the formation of bone marrow fibroblast progenitor cells in vitro (abstract). Blood 70:189A, 1987.
62. Lin SL, T Kikuchi, WJ Pledger, et al: Interferon inhibits the establishment of competence in Go/S-phase transition. Science 233: 356-359, 1986.
63. Gronthos S, LB To, DN Haylock, et al: A differential sensitivity to recombinant human interferon-alpha 2a between normal and chronic myeloid leukaemic peripheral blood granulocyte-macrophage colony-forming units. Leukemia Res 16:153-158, 1992.
64. Messora C, L Bensi, A Veechi, et al: Cytogenic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 86:402-404, 1994.
65. Hino M, E Futami, S Okuno, et al: Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 66:161-162, 1993.
66. Messora C, L Bensi, A Vecchi, et al: Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 86:402-404, 1994.
67. Dewald GW, PI Wright: Chromosome abnormalities in the myeloproliferative disorders. Semin Oncol 22:341-354, 1995.
68. Gale RE, JS Wainscoat: Clonal analysis using X-linked DNA polymorphisms. Br J Haematol 85:2-8, 1993.
69. Talpaz M, G Mavligit, M Keating, et al: Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 99:789-792, 1983.
70. Ludwig H, W Linkesch, H Gisslinger, et al: Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother 25:266-273, 1987.
71. Talpaz M, R Kurzrock, H Kantarjian, et al: Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 86:554-558, 1989.
72. Regev A, P Stark, D Blickstein, et al: Thrombotic complications in essential thrombocythemia with relatively low platelet counts (abstract). Blood 10(suppl 1):583A, 1996.
73. Michiels JJ, PJJ van Genderen, J Lindemans, et al: Erythromelalgic, thrombolic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leukemia Lymphoma 22(suppl 1):47-56, 1996.
74. Gisslinger H, H Ludwig, W Linkesch, et al: Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1:634-637, 1989.
75. Annetts DL, GD Tracy: Idiopathic thrombocythaemia presenting with ischaemia of the toes: Report of three cases. Med J Aust 2: 180-183, 1966.
76. Singh AK, G Wetherley-Mein: Microvascular occlusive lesions in primary thrombocythaemia. Br J Haematol 36:553-564, 1977.
77. Jabaily J, HJ Iland, J Laszlo, et al: Neurologic manifestations of essential thrombocythemia. Ann Intern Med 99:513-518, 1983.
78. Michiels JJ, PJJ Van Genderen, PHP Jansen, et al: Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leukemia Lymphoma 22(suppl 1):65-70, 1996.
79. Geller SA, E Shapiro: Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 77:353-356, 1982.
80. Griesshammer M, H Heimpel, TC Pearson: Essential thrombocythemia and pregnancy. Leukemia Lymphoma 22(suppl 1):57-63, 1996.
81. Beressi AH, A Tefferi, MN Silverstein, et al: Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 155:1217-1222, 1995.
82. Doll DC, QS Ringenberg, JW Yarbro: Management of cancer during pregnancy. Arch Intern Med 148:2058-2064, 1988.
83. Delage R, C Demers, G Cantin, et al: Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Obstet Gynecol 87:814-817, 1996.
84. Perez-Encinas M, JL Bello, S Perez-Crespo, et al: Familial myeloproliferative syndrome. Am J Hematol 46:225-229, 1994.
85. Taft EG, RB Babcock, WB Scharfman, et al: Plateletpheresis in the management of thrombocytosis. Blood 50:927-933, 1977.
86. Goldfinger D, R Thompson, C Lowe, et al: Long-term platelet-pheresis in the management of primary thrombocytosis. Transfusion 19:336-338, 1979.
87. Asano Y, A Okaniwa: In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats. Jikken Dobutsu 36:143-149, 1987.
88. Waysbort A, M Giroux, V Mansat, et al: Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrob Agents Chemother 37:1232-1237, 1993.
89. Salem HH, MB Van der Weyden, IF Young, et al: Pruritus and severe iron deficiency in polycythaemia vera. Br Med J (Clin Res Ed) 285:91-92, 1982.
90. Quesada JR, M Talpaz, A Rios, et al: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 4:234-243, 1986.
91. Jones GJ, LM Itri: Safety and tolerance of recombinant interferon-alpha-2a (Roferon-A) in cancer patients. Cancer 57(suppl 8):1709-1715, 1986.
92. Conlon KC, WJ Urba, JW Smith II, et al: Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65:2237-2242, 1990.
93. Burman P, TH Totterman, K Oberg, et al: Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63:1086-1090, 1986.
94. Akard LP, R Hoffman, L Elias, et al: Alpha-interferon and immune hemolytic anemia (letter to the editor). Ann Intern Med 105:306, 1986.
95. McLaughlin P, M Talpaz, JR Quesada, et al: Immune thrombocytopenia following alpha-interteron therapy in patients with cancer. JAMA 254:1353-1354, 1985.
96. Giralt S, H Kantarjian, M Talpaz: Treatment of chronic myelogenous leukemia. Semin Oncol 22:396-404, 1995.